Vidar Ormaasen

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi request reprint Serum concentrations of protease inhibitors as predictors of HIV-related clinical events in patients on antiretroviral therapy
    Vidar Ormaasen
    Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
    Scand J Infect Dis 38:650-3. 2006
  2. ncbi request reprint HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population
    Vidar Ormaasen
    Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
    Scand J Infect Dis 39:51-7. 2007
  3. ncbi request reprint Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection
    Vidar Ormaasen
    Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
    Scand J Infect Dis 35:383-8. 2003
  4. pmc Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital
    Clara Bratholm
    Department of Infectious Diseases, Oslo University Hospital, Ulleval, Oslo, Norway
    J Antimicrob Chemother 65:1996-2000. 2010
  5. ncbi request reprint A search for optimal criteria in initiating antiretroviral therapy in chronic human immunodeficiency virus infection focusing on CD4 count and HIV RNA
    Vidar Ormaasen
    Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
    Scand J Infect Dis 34:910-7. 2002
  6. doi request reprint HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania
    Asgeir Johannessen
    Department of Infectious Diseases, Oslo University Hospital, Ulleval, Oslo, Norway
    Antivir Ther 15:1003-9. 2010
  7. ncbi request reprint Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment
    Dag Kvale
    Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
    AIDS 20:813-20. 2006
  8. ncbi request reprint [HIV/AIDS--from lethal syndrome to chronic disease]
    Johan N Bruun
    Infeksjonsmedisinsk avdeling Ullevål universitetssykehus 0407 Oslo
    Tidsskr Nor Laegeforen 126:3121-4. 2006
  9. doi request reprint Infectious encephalitis: a description of a Norwegian cohort
    Else Quist-Paulsen
    Department of Infectious Diseases, Oslo University Hospital, Ulleval, Ulleval, Norway
    Scand J Infect Dis 45:179-85. 2013
  10. ncbi request reprint Fatal subarachnoidal haemorrhage in a Norwegian traveller with dengue virus infection
    Mogens Jensenius
    Department of Internal Medicine, Aker University Hospital, Oslo, Norway
    Scand J Infect Dis 39:272-4. 2007

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Serum concentrations of protease inhibitors as predictors of HIV-related clinical events in patients on antiretroviral therapy
    Vidar Ormaasen
    Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
    Scand J Infect Dis 38:650-3. 2006
    ..06-3.90). In conclusion, in this small pilot study we could not show any association between the serum concentrations of PIs and subsequent clinical HIV-related events. Larger studies are needed to explore this subject further...
  2. ncbi request reprint HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population
    Vidar Ormaasen
    Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
    Scand J Infect Dis 39:51-7. 2007
    ..Thus, in the HAART era the mortality in HIV patients was reduced by 80%. However, the mortality in the HAART era was still 4 times higher than in the general population...
  3. ncbi request reprint Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection
    Vidar Ormaasen
    Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
    Scand J Infect Dis 35:383-8. 2003
    ..20, 95% CI 1.05-16.9). Thus, this study indicates that patients with no or a small increase in CD4 counts after 6 months of HAART and low CD4 levels at initiation of therapy have an increased risk of HIV-related disease...
  4. pmc Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital
    Clara Bratholm
    Department of Infectious Diseases, Oslo University Hospital, Ulleval, Oslo, Norway
    J Antimicrob Chemother 65:1996-2000. 2010
    ..To assess long-term virological efficacy and the emergence of drug resistance in children who receive antiretroviral treatment (ART) in rural Tanzania...
  5. ncbi request reprint A search for optimal criteria in initiating antiretroviral therapy in chronic human immunodeficiency virus infection focusing on CD4 count and HIV RNA
    Vidar Ormaasen
    Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
    Scand J Infect Dis 34:910-7. 2002
    ..In conclusion, this study suggests that in chronically HIV-infected individuals, in most cases HAART can be withheld until the CD4 cell count falls towards 0.2 x 10(9)/l...
  6. doi request reprint HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania
    Asgeir Johannessen
    Department of Infectious Diseases, Oslo University Hospital, Ulleval, Oslo, Norway
    Antivir Ther 15:1003-9. 2010
    ..We assessed the performance of DBS in genotypic resistance testing of patients who failed first-line antiretroviral therapy (ART) in rural Tanzania...
  7. ncbi request reprint Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment
    Dag Kvale
    Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
    AIDS 20:813-20. 2006
    ..To examine the immune modulating effects of cyclooxygenase type 2 (COX-2) inhibitors (COX-2i) in HIV-infected patients on combination antiretroviral treatment (CART)...
  8. ncbi request reprint [HIV/AIDS--from lethal syndrome to chronic disease]
    Johan N Bruun
    Infeksjonsmedisinsk avdeling Ullevål universitetssykehus 0407 Oslo
    Tidsskr Nor Laegeforen 126:3121-4. 2006
    ..At its discovery in 1981, AIDS was a fatal syndrome that rapidly led to death. Combination treatment with at least three drugs has radically improved the prognosis...
  9. doi request reprint Infectious encephalitis: a description of a Norwegian cohort
    Else Quist-Paulsen
    Department of Infectious Diseases, Oslo University Hospital, Ulleval, Ulleval, Norway
    Scand J Infect Dis 45:179-85. 2013
    ..Despite extensive diagnostic testing, the causative agent often remains unknown. The aim of this study was to investigate in how many patients the causative agent was found...
  10. ncbi request reprint Fatal subarachnoidal haemorrhage in a Norwegian traveller with dengue virus infection
    Mogens Jensenius
    Department of Internal Medicine, Aker University Hospital, Oslo, Norway
    Scand J Infect Dis 39:272-4. 2007
    ..Our case was consistent with so called 'dengue fever with haemorrhages', a recently described entity that mainly affects adults and may cause severe bleedings also in the absence of DHF...
  11. ncbi request reprint The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
    David A van de Vijver
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, G04 614, 3584 CX Utrecht, The Netherlands
    J Acquir Immune Defic Syndr 41:352-60. 2006
    ..This study compared the genetic barrier between subtypes using some 2000 HIV-1 sequences (>600 of non-B subtype) isolated from anti-retroviral-naive patients in Europe...
  12. ncbi request reprint Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts
    Veronica Miller
    Klinikum der Johann Wolfgang Goethe Universitat, Zentrum der Inneren Medizin, Frankfurt, Germany
    J Infect Dis 186:189-97. 2002
    ..0006; 5.10, P<.0001, respectively, for 4, 3, 2, 1, or no drugs vs. >or=5 drugs). Although reverse causality cannot be excluded, more intense antiviral treatment appears to decrease the risk of progression in immunocompromised patients...
  13. ncbi request reprint Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
    Annemarie M J Wensing
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, The Netherlands
    J Infect Dis 192:958-66. 2005
    ..Widespread transmission of drug-resistant variants has the disturbing potential of limiting future therapy options and affecting the efficacy of postexposure prophylaxis...